CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Toneguzzo P, Regondi V, Corsetto PA, Pietrantonio F, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, Vernieri C, Triulzi T, Pupa SM.
Castagnoli L, et al. Among authors: colombo mp.
J Exp Clin Cancer Res. 2025 Jan 20;44(1):19. doi: 10.1186/s13046-025-03276-z.
J Exp Clin Cancer Res. 2025.
PMID: 39833955
Free article.